RxDoctor Payments Data

Ravin Mehta, PA

Physician Assistant · Charlotte, NCNPI 1356676548

Payments from drug & device makers

$1,568in general payments, 2019–2025

Across 18 payments — averaging $87.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$480
  • Tandem Diabetes Care, Inc.$283
  • Cequr Corporation$239
  • BETA Bionics, Inc.$231
  • Lilly USA, LLC$125
  • Insulet Corporation$81
  • plus $128 from 6 others

What the payments were for

  • Food & beverage$1,54498%
  • Education$242%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,568 in reported general payments places this provider in the 75th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$42,463
Medicare patients
160
Services billed
1,118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide210$300,872
TrulicityDulaglutide68$118,226
MounjaroTirzepatide67$99,830
Humulin R U-500 KwikpenInsulin Regular, Human19$62,086
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/728$52,322
Tresiba Flextouch U-100Insulin Degludec61$47,799
JardianceEmpagliflozin50$46,960
FarxigaDapagliflozin Propanediol50$40,040
Humalog Kwikpen U-200Insulin Lispro13$36,460
Tresiba Flextouch U-200Insulin Degludec36$35,173
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog27$31,629
JanuviaSitagliptin Phosphate27$29,579
Fiasp FlextouchInsulin Aspart (Niacinamide)26$24,836
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog30$19,180
RybelsusSemaglutide16$19,013

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$480$324,322239 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro$125$222,169164 claims
AbbVieSynthroid$15$76413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →